Loading...
XBRU
BIOS
Market cap1mUSD
May 26, Last price  
0.00EUR
Name

Bone Therapeutics SA

Chart & Performance

D1W1MN
XBRU:BIOS chart
P/E
0.06
P/S
—
EPS
0.03
Div Yield, %
—
Shrs. gr., 5y
123.44%
Rev. gr., 5y
-11.50%
Revenues
0k
0000041,0001,000,00001,000,000312,000296,000543,00000
Net income
21m
P
-3,689,000-4,079,000-5,734,000-14,144,000-12,989,000-12,752,000-14,218,000-10,461,000-11,940,000-984,000-2,041,000-28,778,000-4,768,00020,933,000
CFO
-1m
L-52.93%
-4,050,000-3,274,000-3,524,000-11,765,000-11,369,000-11,018,000-12,901,000-10,400,000-16,082,000-12,784,000-1,910,000-3,470,000-2,233,000-1,051,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

BioSenic S.A., a biotechnology company located in Mont-Saint-Guibert, Belgium, is dedicated to progressing clinical therapeutic solutions. The firm utilizes two primary technology platforms: an innovative allogeneic cell and gene therapy system featuring distinct bone marrow-derived mesenchymal stromal cells designed for convenient on-site hospital storage; and an Arsenic Trioxide platform. The latter is deployed in immuno-oncology to target illnesses such as graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The company's leading experimental drug, ALLOB, is currently undergoing a Phase IIb clinical trial for patients with complicated tibial fractures.
URL
http://www.bonetherapeutics.com/
IPO date
Feb 06, 2015
Employees
20
Domiciled in
BE
Incorporated in
BE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT